Great Lakes Advisors LLC Has $503,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Great Lakes Advisors LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,562 shares of the medical research company’s stock after selling 161 shares during the quarter. Great Lakes Advisors LLC’s holdings in IQVIA were worth $503,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC boosted its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. Cantillon Capital Management LLC lifted its holdings in IQVIA by 12.3% in the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after buying an additional 226,017 shares during the period. JPMorgan Chase & Co. boosted its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Nordea Investment Management AB raised its position in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of IQVIA by 3.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,890 shares of the medical research company’s stock valued at $245,026,000 after purchasing an additional 44,991 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on IQV shares. Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Truist Financial reiterated a “buy” rating and issued a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. UBS Group cut their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Citigroup dropped their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Stock Up 2.2 %

IQV opened at $185.40 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.34. The firm has a market capitalization of $32.69 billion, a P/E ratio of 24.72, a PEG ratio of 1.99 and a beta of 1.50. The company’s 50-day moving average is $196.63 and its 200 day moving average is $210.43. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.